Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Calcium mobilization is responsible for Thapsigargin induced Epstein Barr virus lytic reactivation in in vitro immortalized lymphoblstoid cell lines.

Hoji A, Xu S, Bilben H, Rowe DT.

Heliyon. 2018 Nov 16;4(11):e00917. doi: 10.1016/j.heliyon.2018.e00917. eCollection 2018 Nov.

2.

The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection.

Wasil LR, Tomaszewski MJ, Hoji A, Rowe DT.

PLoS One. 2013;8(1):e54010. doi: 10.1371/journal.pone.0054010. Epub 2013 Jan 8.

3.

Endoplasmic reticulum stress causes EBV lytic replication.

Taylor GM, Raghuwanshi SK, Rowe DT, Wadowsky RM, Rosendorff A.

Blood. 2011 Nov 17;118(20):5528-39. doi: 10.1182/blood-2011-04-347112. Epub 2011 Aug 17.

4.

Detection of HHV-8 (human herpesvirus-8) genomes in induced peripheral blood mononuclear cells (PBMCs) from US blood donors.

Qu L, Triulzi DJ, Rowe DT, Jenkins FJ.

Vox Sang. 2011 Apr;100(3):267-71. doi: 10.1111/j.1423-0410.2010.01404.x. Epub 2010 Sep 2.

PMID:
20825598
5.

Cellular factors associated with latency and spontaneous Epstein-Barr virus reactivation in B-lymphoblastoid cell lines.

Davies ML, Xu S, Lyons-Weiler J, Rosendorff A, Webber SA, Wasil LR, Metes D, Rowe DT.

Virology. 2010 Apr 25;400(1):53-67. doi: 10.1016/j.virol.2010.01.002. Epub 2010 Feb 11.

6.

Effects of storage and leukoreduction on lymphocytes and Epstein-Barr virus genomes in platelet concentrates.

Qu L, Rowe DT, Donnenberg AD, Griffin DL, Triulzi DJ.

Transfusion. 2009 Aug;49(8):1580-3. doi: 10.1111/j.1537-2995.2009.02197.x.

7.

Chronic high Epstein-Barr viral load carriage in pediatric liver transplant recipients.

Green M, Soltys K, Rowe DT, Webber SA, Mazareigos G.

Pediatr Transplant. 2009 May;13(3):319-23. doi: 10.1111/j.1399-3046.2008.00926.x. Epub 2008 Apr 6.

PMID:
18397216
8.

Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children.

Bingler MA, Feingold B, Miller SA, Quivers E, Michaels MG, Green M, Wadowsky RM, Rowe DT, Webber SA.

Am J Transplant. 2008 Feb;8(2):442-5. doi: 10.1111/j.1600-6143.2007.02080.x.

9.
10.

Stability of lymphocytes and Epstein-Barr virus during red blood cell storage.

Qu L, Triulzi DJ, Rowe DT, Griffin DL, Donnenberg AD.

Vox Sang. 2007 Feb;92(2):125-9.

PMID:
17298574
11.

Progress in the development of the DexAide right ventricular assist device.

Fukamachi K, Ootaki Y, Horvath DJ, Massiello AL, Kamohara K, Akiyama M, Cingoz F, Ootaki C, Kopcak MW Jr, Dessoffy R, Liu J, Chen JF, Zhou Q, Benefit S, Golding LA, Alfini S, Rowe DT.

ASAIO J. 2006 Nov-Dec;52(6):630-3. Review.

PMID:
17117051
12.

DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes.

Rappocciolo G, Piazza P, Fuller CL, Reinhart TA, Watkins SC, Rowe DT, Jais M, Gupta P, Rinaldo CR.

PLoS Pathog. 2006 Jul;2(7):e70.

13.

Herpesvirus infections in organ transplant recipients.

Jenkins FJ, Rowe DT, Rinaldo CR Jr.

Clin Diagn Lab Immunol. 2003 Jan;10(1):1-7. Review. No abstract available.

14.

Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome.

Holmes RD, Orban-Eller K, Karrer FR, Rowe DT, Narkewicz MR, Sokol RJ.

Transplantation. 2002 Aug 15;74(3):367-72.

PMID:
12177616
15.
16.

Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease.

Rowe DT, Webber S, Schauer EM, Reyes J, Green M.

Transpl Infect Dis. 2001 Jun;3(2):79-87. Review.

PMID:
11395973
17.

Serum sCD23 level in patients with AIDS-related non-Hodgkin's lymphoma is associated with absence of Epstein-Barr virus in tumor tissue.

Schroeder JR, Saah AJ, Ambinder RF, Martinez-Maza O, Crabb Breen E, Variakojis D, Margolick JB, Jacobson LP, Rowe DT, Hoover DR.

Clin Immunol. 1999 Dec;93(3):239-44.

PMID:
10600334
18.

Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma.

Schroeder JR, Saah AJ, Hoover DR, Margolick JB, Ambinder RF, Martinez-Maza O, Breen EC, Jacobson LP, Variakojis D, Rowe DT, Armenian HK.

Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84.

19.

Natural history of Epstein-Barr viral load in peripheral blood of pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disorder.

Cacciarelli TV, Reyes J, Mazariegos GV, Sigurdsson L, Rowe DT, Fung JJ, Green M.

Transplant Proc. 1999 Feb-Mar;31(1-2):488-9. No abstract available.

PMID:
10083204
20.

Epstein-Barr virus immortalization and latency.

Rowe DT.

Front Biosci. 1999 Mar 15;4:D346-71. Review.

PMID:
10077545
21.

Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.

Green M, Cacciarelli TV, Mazariegos GV, Sigurdsson L, Qu L, Rowe DT, Reyes J.

Transplantation. 1998 Dec 27;66(12):1641-4.

PMID:
9884252
22.
24.
27.

Cell growth effects of Epstein-Barr virus leader protein.

Allan GJ, Inman GJ, Parker BD, Rowe DT, Farrell PJ.

J Gen Virol. 1992 Jun;73 ( Pt 6):1547-51.

PMID:
1318948
28.
29.

Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Young LS, Lau R, Rowe M, Niedobitek G, Packham G, Shanahan F, Rowe DT, Greenspan D, Greenspan JS, Rickinson AB, et al.

J Virol. 1991 Jun;65(6):2868-74.

30.
31.

Structure and function of the Epstein-Barr virus BZLF1 protein.

Packham G, Economou A, Rooney CM, Rowe DT, Farrell PJ.

J Virol. 1990 May;64(5):2110-6.

33.
34.
35.
37.

Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, Rickinson AB.

EMBO J. 1987 Sep;6(9):2743-51.

38.
39.

Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells.

Rowe DT, Rowe M, Evan GI, Wallace LE, Farrell PJ, Rickinson AB.

EMBO J. 1986 Oct;5(10):2599-607.

41.

Protein kinase and ATP-binding activity associated with the 72-kdalton single-stranded DNA-binding protein from early region 2A of human adenovirus type 5.

Branton PE, Evelegh M, Rowe DT, Graham FL, Bacchetti S.

Can J Biochem Cell Biol. 1985 Sep;63(9):941-52.

PMID:
3907803
43.
44.

Transformation by human adenoviruses.

Graham FL, Rowe DT, McKinnon R, Bacchetti S, Ruben M, Branton PE.

J Cell Physiol Suppl. 1984;3:151-63. No abstract available.

PMID:
6611340
45.

Intracellular localization of adenovirus type 5 tumor antigens in productively infected cells.

Rowe DT, Graham FL, Branton PE.

Virology. 1983 Sep;129(2):456-68.

PMID:
6353747
46.

Characterization of human adenovirus type 5 early region 1A polypeptides using antitumor sera and an antiserum specific for the carboxy terminus.

Rowe DT, Yee SP, Otis J, Graham FL, Branton PE.

Virology. 1983 Jun;127(2):253-71. No abstract available.

PMID:
6868367
47.
48.
49.

Mapping of a 14,000-dalton antigen to early region 4 of the human adenovirus 5 genome.

Downey JF, Rowe DT, Bacchetti S, Graham FL, Bayley ST.

J Virol. 1983 Feb;45(2):514-23.

Supplemental Content

Support Center